Avatrombopag

Indication

Treatment of primary chronic immune thrombocytopenia - NICE TA853

NICE TA 853 - Avatrombopag for treating primary chronic immune thrombocytopenia

Red

Brand:

Doptelet

Nice TA:

853

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Blood and Nutrition

Background

Avatrombopag is recommended, within its marketing authorisation, as an option for treating primary chronic immune thrombocytopenia (ITP) refractory to other treatments (for example, corticosteroids, immunoglobulins) in adults. It is only recommended if the company provides it according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 28 - Feb - 2023

Breadcrumb

Avatrombopag

Indication

Background

Recommendation

Decisions of Lancashire local decision making groups